| Document |
Document Title |
|
WO/2022/254034A1 |
The present invention concerns a compound having the formula (I), wherein: R1 is selected from the group consisting of: H, F, (C1-C6)alkoxy, and halo(C1-C6)alkyl; and R2 is an optionally substituted heteroaryl group, as well as processes...
|
|
WO/2022/256075A1 |
Pyrimidine and Pyridine amine containing compounds are described herein that are enzyme p70S6K inhibitors useful in the treatment of S6K-dependent or S6K-mediated diseases and conditions, including but not limited to cancer, fibrotic met...
|
|
WO/2022/247770A1 |
A nitrogen-containing heterocyclic compound, a preparation method therefor and an application thereof. A nitrogen-containing heterocyclic compound represented by formula I, a pharmaceutically acceptable salt thereof, a stereoisomer there...
|
|
WO/2022/251647A1 |
This invention is in the field of medicinal pharmacology. In particular, the present invention relates to pharmaceutical agents which function as inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral replicatio...
|
|
WO/2022/244765A1 |
[Problem] To provide a novel eye drop for suppressing myopia. [Solution] The above problem has been solved by using an eye drop containing bunazosin as an eye drop for suppressing myopia. This eye drop for suppressing myopia is effective...
|
|
WO/2022/241186A1 |
Disclosed herein are compositions and pharmaceutical formulations comprising a functionally selected β-arrestin-biased NTSR1 ligand (such as SBI-553 and SBI-810) and methods of using those compositions and pharmaceutical formulations fo...
|
|
WO/2022/238694A1 |
Compounds of formula (I) or formula (II) are disclosed: Wherein Y1, Y2, and Y3 are independently selected from C-R1 or N. Such compounds find use as antibiotics and antifungals.
|
|
WO/2022/240826A1 |
The present invention relates generally to compositions and methods for treating cancer, e.g. by using the compounds of formula (I). Provided herein are substituted bicyclic heteroaryl derivative compounds and pharmaceutical compositions...
|
|
WO/2022/237456A1 |
Disclosed is the use of a series of 4-arylaminoquinazoline hydroxamic acid compounds in the preparation of a drug for treating neuropathic pain diseases, and specifically, the use of a compound as represented by formula III-2, a tautomer...
|
|
WO/2022/236133A1 |
Provided herein are fatty acid amide (FAAH) cleavable prodrugs of thyromimetics and pharmaceutical compositions comprising these compounds with at least one pharmaceutically acceptable excipient further comprising a peripherally restrict...
|
|
WO/2022/228218A1 |
An application of a quinazoline compound and a pharmaceutical composition. The quinazoline compound is the quinazoline compound shown in formula A, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharma...
|
|
WO/2022/228577A1 |
The present invention provides a novel benzotropone derivative, and a preparation method therefor and an application thereof. The novel benzotropone derivative has a structure as represented by general formula (I) or formula (II), wherei...
|
|
WO/2022/232259A1 |
Provided herein are soluble adenylyl cyclase (sAC) inhibitors and uses thereof. In one aspect, provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, s...
|
|
WO/2022/232632A1 |
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodru...
|
|
WO/2022/226118A1 |
The invention encompasses novel dihydroquinoxalinone compounds with significantly improved water solubility and reduced toxicity to achieve higher therapeutic indexes and the treatment of cancer, virus infections, and inflammation using ...
|
|
WO/2022/223033A1 |
An SOS1 degrading agent and a preparation method therefor and an application thereof. Specifically, disclosed is a compound represented by formula I: S-L-E(I), wherein L is a linker chain, which connects S and E by means of covalent bond...
|
|
WO/2022/225866A1 |
The disclosure relates to quinazoline derivatives, pharmaceutical compositions, and therapeutic methods related thereto. In certain embodiments, this disclosure relates to compounds and methods of treating or preventing a Nox-related dis...
|
|
WO/2022/223034A1 |
An SOS1 degradation agent and a preparation method therefor and an application thereof. Specifically, disclosed is a compound of formula I: S-L-E(I), wherein L is a linking chain, which links S and E by means of covalent bonds; E is a sm...
|
|
WO/2022/223039A1 |
An SOS1 degrader, a preparation method therefor and an application thereof. Specifically, the present invention relates to a compound of formula I: S-L-E (I), wherein S is a small molecule compound capable of inhibiting the activity of a...
|
|
WO/2022/217364A1 |
A new class of antibiotics, namely, mercaptoacetophenone aminohydrazones, their analogues, their method of preparation, their salts, and their use in cases of bacterial infections, either alone or with other compounds.
|
|
WO/2022/218914A1 |
The present invention refers to a process for preparing carbonyl-containing compounds of formula (Ia), (Ib) or (Ic) from Bisphenol A-based Polycarbonate and appropriate nucleophiles in the presence of imidazole or a derivative thereof as...
|
|
WO/2022/217295A1 |
Described are compounds of formula (I), or pharmaceutically acceptable salts thereof: (I) that are useful for control of protein expression with eDHFR tags and methods of controlling protein expression with such compounds, as well as kit...
|
|
WO/2022/213601A1 |
An organic light-emitting diode structure and a display apparatus are provided. A light-emitting layer, a hole blocking layer and an electron blocking layer in the organic light-emitting diode structure meet the following conditions: T1(...
|
|
WO/2022/217239A1 |
Disclosed herein are compounds which inhibit PU.1, pharmaceutical formulations, and methods of treatment of PU.1-mediated diseases, such as Alzheimer's disease, inflammation, and diseases related to excessive myelin uptake.
|
|
WO/2022/217118A1 |
The disclosure provides pyrimidine based derivatives of Formula (I), (I-a), (I-b), (I-c), (I-d), (II), or (III), or salts thereof, for the modulation of Ras/Raf signaling. In another aspect, the present disclosure provides methods for th...
|
|
WO/2022/214009A1 |
Provided are a compound, which has a structure of formula (I) and is capable of inhibiting HPK1 kinase activity, and a pharmaceutical composition comprising the compound. Further provided is the use of the compound in the prevention and/...
|
|
WO/2022/216750A1 |
Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.
|
|
WO/2022/209428A1 |
The present disclosure provides a feature of efficiently detecting a wider variety of RNA higher-order structures including non-Watson-Crick base pair-type higher order structures. The method for analyzing the RNA higher-order structure ...
|
|
WO/2022/207752A1 |
A compound comprising the formula (I), wherein each X1 is independently selected from C, N, O and S; each Y is independently selected from C and N; Z1 is independently selected from C and N; each X1 may independently be unsubstituted, or...
|
|
WO/2022/206797A1 |
Compounds of formula A, a method for using said compounds as an EGFR inhibitor, and a pharmaceutical composition comprising said compounds. The compounds can be used to treat, prevent or ameliorate diseases or conditions such as cancers ...
|
|
WO/2022/212815A1 |
Described are 6-aryl quinazolin-4(3H)-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treat...
|
|
WO/2022/204452A1 |
The present application relates to compounds of formula (I'), pharmaceutically acceptable compositions thereof, and methods of using the same. The compounds of formula I' are TEAD inhibitors, useful in the treatment of cancer.
|
|
WO/2022/203466A1 |
The present invention provides a pyrimidine compound of chemical formula 1, a pharmaceutical composition containing same for preventing or treating a LRRK2-mediated or related disease (for example, Parkinson's disease), and a method for ...
|
|
WO/2022/201097A1 |
Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administerin...
|
|
WO/2022/204299A1 |
Compounds having activity as inhibitors of LRRK2 kinase are provided. The compounds have Structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R1a, R1b, R2, and L are as defined herein. Meth...
|
|
WO/2022/204080A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2022/199815A1 |
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 2 (LPA2), particularly the invention relates to compounds that are 8-cyclo-substituted quinazoline derivatives, methods of prepar...
|
|
WO/2022/202814A1 |
The present invention relates to a method for producing the pyrimidine compound of formula (1) which is useful as a medicine. In the formula, R1 is a C1-4 alkyl group or the like, R2 is a hydrogen atom or the like, and each of m and n is...
|
|
WO/2022/199589A1 |
A series of pyrimidine derivatives and the use thereof in the preparation of a drug for treating related diseases. Specifically disclosed are a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, and the...
|
|
WO/2022/201155A1 |
The present invention relates to a novel nitration process of 2- chloro -4- fluorobenzoic acid to 2-chloro-4- fluoro-5-nitrobenzoic acid, 2-chloro-4- f luoro-3 -nitrobenzoic acid and 3, 5-dinitro-2-chloro-4- fluorobenzoic acid; purifying...
|
|
WO/2022/194248A1 |
A CTLA-4 small molecule degradation agent and an application thereof. The CTLA-4 small molecule degradation agent comprises a compound having the structure represented by formula I or a pharmaceutically acceptable salt, an ester, a deute...
|
|
WO/2022/195522A1 |
The present invention relates to a composition comprising at least one active agent that can inhibit anoctamin 6 protein and a method of treating or preventing disease, disorder, or condition associated with virus infection by administer...
|
|
WO/2022/197862A1 |
Provided herein are SOS1 protein degraders, for example, a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of ...
|
|
WO/2022/194066A1 |
Provided are a compound having KRAS G12D modulating activity, a preparation method for same, and a pharmaceutical composition comprising same.
|
|
WO/2022/194265A1 |
Provided are a quinazoline-based compound, a composition, and an application of the quinazoline-based compound, in particular, relating to a compound represented by formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt ...
|
|
WO/2022/188819A1 |
The present invention relates to an SOS1 proteolysis modulator, a preparation method therefor and the application thereof. In particular, the compound of the present invention has a structure represented by formula (I). Further disclosed...
|
|
WO/2022/188735A1 |
Provided are heterocyclics as inhibitors of HPK1, in particular a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that is useful for treatment of HPK1 mediate...
|
|
WO/2022/191312A1 |
[Abstract] [Problem] To provide a method for producing a dealkoxyphenylation product with high yield from a substrate, e.g., a sugar, which is bonded to an alkoxyphenyl group through an oxygen atom. [Solution] A substrate that is bonded ...
|
|
WO/2022/189599A1 |
The present invention relates to anhydrous crystalline forms of mavacamten and processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising an anhydrous crystalline form of the present in...
|
|
WO/2022/185322A1 |
The present invention relates to novel solid forms of saflufenacil-sodium or saflufenacil-potassium. The present invention further relates to a process of making said novel solid forms of saflufenacil-sodium or saflufenacil-potassium. St...
|
